60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Washington, District Of Columbia.…
Join 60 Degrees Pharmaceuticals' Live Investor Webinar: Advancing Tafenoquine for Babesiosis While Expanding ARAKODA(R) Commercialization
60 Degrees Pharmaceuticals (NASDAQ: SXTP) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 3 employees.
The shares were at 0.4682 USD on 20 November 2026, down 90.5% over 52 weeks. Its 52-week range is 0.4600 USD to 8.620 USD: the price is 94.6% below the high and 1.8% above the low.
Its market capitalisation is 2.10M USD.
60 Degrees Pharmaceuticals reports return on equity of -212.7% and revenue down 55.9% year over year.
It holds more cash than debt, a net cash position of 155.79K USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.